oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Riflux – recalled product

Riflux

CRITICAL 05.12.2019

Contamination of the active substance Ranitidine with N-nitrosodimethylamine (NDMA) was detected, constituting a quality defect and a potential risk to patients’ health. Potential effects: possible toxic and carcinogenic effects during long-term use.

Debridat – recalled product

Debridat

CRITICAL 22.11.2019

Risk of a potential quality defect consisting in the presence of a foreign body in the product. Potential effects: mechanical injuries, gastrointestinal complications, risk to health or life.

Debridat – recalled product

Debridat

CRITICAL 22.11.2019

Risk of the presence of a foreign body in the medicinal product, possibly due to a potential quality defect. Potential effects: mechanical damage to the gastrointestinal tract, complications, need for medical intervention.

Debridat – recalled product

Debridat

CRITICAL 22.11.2019

Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension. Potential effects: mechanical damage, complications, irritation of the gastrointestinal tract.

Debridat – recalled product

Debridat

CRITICAL 22.11.2019

A potential quality defect was reported due to the risk of a foreign body being present in the product, which may pose a real and direct risk to patients’ health or life. Potential effects: complications, tissue damage, life-threatening events.

Debridat – recalled product

Debridat

CRITICAL 22.11.2019

Risk of the presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may cause gastrointestinal damage or other mechanical complications during use. Potential effects: mechanical injuries, complications, risk to health or life.

Debridat – recalled product

Debridat

CRITICAL 22.11.2019

Risk of a quality defect in the medicinal product Debridat, 7.87 mg/g, granules for oral suspension, due to the risk of the presence of a foreign body in the product. Potential effects: gastrointestinal injuries, complications, possible threat to the patient’s health or life.

Debridat – recalled product

Debridat

CRITICAL 20.11.2019

Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may expose the patient to mechanical damage of the gastrointestinal tract or other complications during use. Potential effects: injuries, complications, health risk.

Apra-swift – recalled product

Apra-swift

HIGH 20.11.2019

A printing inconsistency in the dose on one side of the outer packaging was found (15 mg stated incorrectly, it should be 30 mg). Potential effects: improper dosing, lack of treatment efficacy or adverse effects.

Raniberl Max – recalled product

Raniberl Max

HIGH 08.11.2019

Contamination of the active substance ranitidine with N-nitrosodimethylamine (NDMA) was detected, causing the batches to be deemed non-compliant with quality requirements and potentially hazardous to patients’ health or life. Potential effects: carcinogenic action, organ damage, general poisoning.

Lakcid forte – recalled product

Lakcid forte

LOW 06.11.2019

The test showed that the product sample does not comply with the specification regarding the CFU count of lactic acid bacteria (Lactobacillus rhamnosus), which may mean a lower content of live probiotic bacteria than declared. Potential effects: lack of treatment efficacy, possible worsening of symptoms, delay of therapy.

Lakcid forte – recalled product

Lakcid forte

MEDIUM 06.11.2019

It was found that the product sample does not comply with the specification regarding the number of lactic acid bacteria CFU, which may lead to reduced therapeutic effectiveness of the probiotic preparation. Potential effects: reduced treatment effectiveness, lack of the expected probiotic effect.

NuTRIflex Omega plus – recalled product

NuTRIflex Omega plus

CRITICAL 05.11.2019

Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating a quality defect of a solution intended for intravenous infusion. Potential effects: lack of therapeutic efficacy, metabolic disturbances, complications during parenteral nutrition.

Flavamed – recalled product

Flavamed

CRITICAL 05.11.2019

A possible increased level of impurity E was identified in batches manufactured using glass bottles from one of the suppliers, which constitutes a quality defect of the medicinal product. Potential effects: possible adverse reactions or reduced treatment safety.

NuTRIflex Omega special – recalled product

NuTRIflex Omega special

CRITICAL 05.11.2019

Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating potential instability of the intravenously administered preparation. Potential effects: lack of treatment efficacy, infusion-related complications, adverse reactions.

Flavamed – recalled product

Flavamed

MEDIUM 30.10.2019

Tests by the National Medicines Institute confirmed that the sample of Flavamed batch 82014 did not meet purity specification requirements due to an exceeded level of impurity E, which makes a potential health risk for patients plausible. Potential effects: possible adverse reactions, complications, reduced treatment safety.

Ranimax Teva – recalled product

Ranimax Teva

CRITICAL 29.10.2019

In connection with information from the Rapid Alert system on detection of N-nitrosodimethylamine (NDMA) contamination in products containing ranitidine and the substantiated potential risk to patients’ health or life. Potential effects: long-term exposure to NDMA, possible carcinogenic action and other serious toxic effects.

Ranigast Pro – recalled product

Ranigast Pro

CRITICAL 28.10.2019

Contamination of the active substance Ranitidinum with N-nitrosodimethylamine (NDMA) was detected, representing a quality defect of the product and potentially endangering patients’ health or life. Potential effects: poisoning, carcinogenic effects, serious health complications.

Ranigast – recalled product

Ranigast

CRITICAL 28.10.2019

The presence of N-nitrosodimethylamine (NDMA) contamination was confirmed in the active substance ranitidine used to manufacture batches of Ranigast 0.5 mg/ml, solution for infusion, which may pose a potential risk to patients' health. Potencjalne skutki: increased risk of adverse effects, including possible carcinogenic action with long-term exposure.

Ranigast – recalled product

Ranigast

CRITICAL 28.10.2019

The presence of N-nitrosodimethylamine (NDMA) contamination was found in the active substance ranitidine used to manufacture the Ranigast 150 mg, film-coated tablet batches, which constitutes a quality defect of the medicinal product. Potential effects: increased risk of carcinogenic effects and toxic liver damage.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.